These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26615988)

  • 1. BRAF in metastatic colorectal cancer: the future starts now.
    Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
    Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
    Strickler JH; Wu C; Bekaii-Saab T
    Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Lee HM; Morris V; Napolitano S; Kopetz S
    Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic
    Forsythe N; Refaat A; Javadi A; Khawaja H; Weir JA; Emam H; Allen WL; Burkamp F; Popovici V; Jithesh PV; Isella C; Labonte MJ; Mills IG; Johnston PG; Van Schaeybroeck S
    Mol Cancer Ther; 2018 Jun; 17(6):1280-1290. PubMed ID: 29483217
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
    Abdel-Rahman O
    Future Oncol; 2016 Jan; 12(1):25-30. PubMed ID: 26616508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.
    Temraz S; Alameddine R; Shamseddine A
    Curr Opin Oncol; 2015 May; 27(3):276-81. PubMed ID: 25774859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
    Wong V; Lee M; Wong R; Tie J; Shapiro J; Desai J; Nott L; Steel S; Burge M; Ma B; Khattak A; Hong W; Gibbs P
    Target Oncol; 2021 Mar; 16(2):227-236. PubMed ID: 33599905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
    Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
    J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
    Tie J; Desai J
    Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications.
    Angerilli V; Sabella G; Centonze G; Lonardi S; Bergamo F; Mangogna A; Pietrantonio F; Fassan M; Milione M
    Crit Rev Oncol Hematol; 2022 Apr; 172():103647. PubMed ID: 35248712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in BRAF-mutant metastatic colorectal cancer.
    Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
    Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
    Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
    Sclafani F; Gullo G; Sheahan K; Crown J
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.
    Sanz-Garcia E; Argiles G; Elez E; Tabernero J
    Ann Oncol; 2017 Nov; 28(11):2648-2657. PubMed ID: 29045527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
    Cohen R; Liu H; Fiskum J; Adams R; Chibaudel B; Maughan TS; Van Cutsem E; Venook A; Douillard JY; Heinemann V; Ja Punt C; Falcone A; Bokemeyer C; Kaplan R; Lenz HJ; Koopman M; Yoshino T; Zalcberg J; Grothey A; de Gramont A; Shi Q; André T
    J Natl Cancer Inst; 2021 Oct; 113(10):1386-1395. PubMed ID: 33734401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
    Korphaisarn K; Kopetz S
    Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encorafenib, binimetinib and cetuximab combined therapy for patients with
    Huijberts SC; van Geel RM; Bernards R; Beijnen JH; Steeghs N
    Future Oncol; 2020 Feb; 16(6):161-173. PubMed ID: 32027186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.